{"id":"bcg-tokyo-172-strain-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Dysuria"},{"rate":null,"effect":"Urinary frequency"},{"rate":null,"effect":"Hematuria"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Systemic BCG infection (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"BCG works as an immunotherapeutic agent by activating innate and adaptive immune responses through toll-like receptor signaling and antigen presentation. When instilled intravesically in bladder cancer, it promotes local immune infiltration and systemic anti-tumor immunity, helping prevent recurrence and progression of non-muscle-invasive bladder cancer.","oneSentence":"BCG Tokyo-172 is a live attenuated Mycobacterium bovis strain that stimulates the immune system to recognize and attack cancer cells, particularly in bladder cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:03:50.084Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-muscle-invasive bladder cancer (NMIBC), high-risk disease"}]},"trialDetails":[{"nctId":"NCT03091660","phase":"PHASE3","title":"S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"SWOG Cancer Research Network","startDate":"2017-02-24","conditions":"Stage 0 Bladder Urothelial Carcinoma, Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma","enrollment":1000}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bacillus Calmette-Guerin Tokyo-172 Strain Solution","Immunobladder"],"phase":"phase_3","status":"active","brandName":"BCG Tokyo-172 Strain Solution","genericName":"BCG Tokyo-172 Strain Solution","companyName":"SWOG Cancer Research Network","companyId":"swog-cancer-research-network","modality":"Biologic","firstApprovalDate":"","aiSummary":"BCG Tokyo-172 is a live attenuated Mycobacterium bovis strain that stimulates the immune system to recognize and attack cancer cells, particularly in bladder cancer. Used for Non-muscle-invasive bladder cancer (NMIBC), high-risk disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}